hVIVO (LSE:HVO) has expanded its clinical research capabilities into dermatology and women’s health through the acquisition of CRS Clinical Research Services Berlin, strengthening the group’s presence in Germany and broadening its exposure to new therapeutic markets.
CRS Berlin operates a specialist Phase I/II clinical research unit with particular expertise in dermatology and women’s health. The business has completed more than 350 studies and generated revenue of €10 million during 2025, bringing an established operational platform and pharmaceutical client relationships into the hVIVO group.
The acquisition has been structured with a nominal upfront consideration alongside a three-year earnout linked to future revenue performance. This structure provides hVIVO with an opportunity to expand its capabilities while aligning additional consideration with the performance of the acquired business.
CRS Berlin will be integrated into hVIVO’s existing German network, giving the group greater access to specialist patient populations and increasing its capacity to undertake larger and more complex early-phase clinical trials across multiple sites.
Management expects the transaction to be immediately earnings accretive and to make a positive contribution to both revenue and EBITDA from FY26. CRS Berlin also brings an orderbook of approximately €10 million, providing visibility over its initial contribution to the enlarged group.
Strategically, the acquisition extends hVIVO into the growing dermatology and women’s health clinical research markets while further diversifying the group’s therapeutic exposure. The additional capabilities complement its established activities across infectious diseases, respiratory, cardiometabolic, immunology and other primary care indications.
Combining CRS Berlin with hVIVO’s wider operations also creates opportunities to offer clients a broader range of integrated services and potentially cross-sell capabilities across its clinical trials, laboratory, consulting and human challenge businesses.
The transaction further strengthens hVIVO’s multi-site operating model across the UK and Germany, providing additional scale and specialist expertise as the company continues to develop its position as an international early-phase clinical development partner.
More about hVIVO plc
hVIVO plc is a purpose-built, full-service international clinical development partner specialising in early-phase research for pharmaceutical and biotechnology companies.
The company is a global leader in human challenge trials and also provides conventional clinical trial services, laboratory capabilities and consulting.
Its therapeutic expertise spans infectious diseases, respiratory conditions, cardiometabolic diseases, immunology and primary care indications, with the acquisition of CRS Berlin adding specialist capabilities in dermatology and women’s health.
Leave a Reply